The Big Pharma stock is up by more than 50% in 2024, but investment-bank analysts think it has more room to run.Shares of Eli Lilly (LLY 3.06%) have already soared by about 58% in 2024. Despite the run-up, many analysts on Wall Street think the pharmaceutical stock can climb a lot higher. Bank of America analyst Geoff Meacham is so encouraged by the company's recent progress with obesity, diabetes, and Alzheimer's disease that he thinks the stock can climb to $1,150 per share.Meacham's recently updated pric ...